|The Future of Medicine Through Bioengineering - Ayden Jacob ™|
Dr. Rémi Rabasa-Lhoret from the IRCM and Dr. Laurent Legault from the Montreal Children's Hospital, conducted the first pediatric outpatient study to compare three alternative treatments for type 1 diabetes. "The dual-hormone artificial pancreas has the potential to reduce hypoglycemia more than the other strategies, but the relative benefits provided by glucagon had not yet been assessed in outpatient settings," says Dr. Rabasa-Lhoret, endocrinologist and clinical researcher at the IRCM. "Demonstrating the effectiveness of the artificial pancreas among children in an uncontrolled environment is an important step in making this technology available to the general public in the near future." "During our study, we also found that no participant using the dual-hormone system experienced a nocturnal hypoglycaemia event requiring treatment," explains Ahmad Haidar, PhD. "This is significant when considering that hypoglycaemic events occurred on 16 per cent of nights with conventional pump therapy, and 4 per cent of nights with the single-hormone artificial pancreas."